The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer

BACKGROUND: In FRESCO trial, a phase III study of fruquintinib demonstrated a significant improvement on the overall survival (OS) of patients with metastatic colorectal cancer (mCRC) who failed to response to available standard treatments. The aim of the current study was to evaluate the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yan, Qu, Tao, Zhang, Honggang, Sun, Yongkun, Cui, Chengxu, Chi, Yihebali, Zhang, Wen, Wang, Xingyuan, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357312/
https://www.ncbi.nlm.nih.gov/pubmed/34393513
http://dx.doi.org/10.2147/CMAR.S313275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357312/
https://www.ncbi.nlm.nih.gov/pubmed/34393513
http://dx.doi.org/10.2147/CMAR.S313275

Ejemplares similares